AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
Healthcare
$47.40 -1.88%
-$1.07 today
- Market cap
- $1.41B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
52W Low $11.40High $72.36
Volume 0.51M
Average 0.76M
Income Statement
Follow revenue through to earnings.
Revenue
$234.60M
FY 2025 · Annual
+157.0% YoYOperating Income
$47.90M
FY 2025 · Annual
Net Income
-$13.23M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.18M | 10.29M | 17.16M | 91.28M | 234.6M |
| Cost of Revenue | 98.5M | 88.8M | 132.28M | 163.84M | 2.42M |
| Gross Profit | (35.32M) | (78.51M) | (115.13M) | (72.56M) | 232.18M |
| Gross Margin | -55.9% | -763.2% | -671.0% | -79.5% | 99.0% |
| Research & Development | 98.5M | 88.8M | 139.62M | 163.84M | 135.97M |
| Selling, General & Admin | 21.49M | 36.64M | 41.95M | 42.39M | 50.74M |
| Operating Expenses | 21.49M | 36.64M | 49.29M | 42.39M | 184.28M |
| Depreciation & Amortization | 2.09M | 2.34M | 652K | 2.4M | 2.42M |
| EBITDA | (55.71M) | (105.26M) | (156.42M) | (92.74M) | 69.25M |
| EBITDA Margin | -88.2% | -1023.2% | -911.7% | -101.6% | 29.5% |
| Operating Income | (56.81M) | (115.15M) | (164.41M) | (114.95M) | 47.9M |
| Operating Margin | -89.9% | -1119.4% | -958.3% | -125.9% | 20.4% |
| Interest Income | 431K | 7.55M | 18.87M | 19.79M | 13.5M |
| Interest Expense | 1.45M | 21.11M | 18.08M | 50.09M | 79.89M |
| Other Income / Expenses | (982K) | (13.55M) | 788K | (30.28M) | (60.96M) |
| Income Before Tax | (57.8M) | (128.7M) | (163.62M) | (145.23M) | (13.07M) |
| Pre-Tax Margin | -91.5% | -1251.1% | -953.7% | -159.1% | -5.6% |
| Income Tax Expense | 0 | 24K | (4K) | 3K | 164K |
| Net Income | (57.8M) | (128.72M) | (163.62M) | (145.23M) | (13.23M) |
| Net Margin | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
| EPS (Basic) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| EPS (Diluted) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| 27.43M | 28.17M | 26.92M | 28.38M | 27.79M | |
| 27.43M | 28.17M | 26.92M | 28.38M | 31.34M |
ANAB Earnings Waterfall · TTM
NASDAQ:ANAB · Revenue to Net Income
Key Ratios
EPS$-1.08
Gross Margin71.6%
Net Margin-78.7%
P/E Ratio1.5
P/S Ratio19.2
Analysis
$232.4M of revenue converted into -$26.8M of net income for the selected period. Gross margin is 71.6% and net margin is -78.7%, showing how much revenue survives after costs and taxes. EPS is $-1.08, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 10-KT | 10-KT filing | Sep 21, 2026 | |
| 8-K | Current report | Sep 21, 2026 |
How much revenue does ANAB generate?
AnaptysBio, Inc. (ANAB) reported $234.60M of revenue in fiscal 2025.
Is ANAB profitable?
AnaptysBio, Inc. (ANAB) reported -$13.23M of net income, with a net margin of -5.6%.
Continue the stock analysis
Jump to another research area for this company.